On September 10, 2022, SpringWorks Therapeutics, Inc. ("SpringWorks" or the "Company") reported that data from the Phase 3 DeFi trial of nirogacestat, an investigational oral gamma secretase inhibitor, in adult patients with progressing desmoid tumors, at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2022 (Presentation, SpringWorks Therapeutics, SEP 10, 2022, View Source [SID1234619433]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!